Cargando…

Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations

[Image: see text] Oncogenic mutations of Ras at codons 12, 13, or 61, that render the protein constitutively active, are found in ∼16% of all cancer cases. Among the three major Ras isoforms, KRAS is the most frequently mutated isoform in cancer. Each Ras isoform and tumor type displays a distinct p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammond, Dean E., Mageean, Craig J., Rusilowicz, Emma V., Wickenden, Julie. A., Clague, Michael J., Prior, Ian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356034/
https://www.ncbi.nlm.nih.gov/pubmed/25599653
http://dx.doi.org/10.1021/pr501191a
_version_ 1782360942041890816
author Hammond, Dean E.
Mageean, Craig J.
Rusilowicz, Emma V.
Wickenden, Julie. A.
Clague, Michael J.
Prior, Ian A.
author_facet Hammond, Dean E.
Mageean, Craig J.
Rusilowicz, Emma V.
Wickenden, Julie. A.
Clague, Michael J.
Prior, Ian A.
author_sort Hammond, Dean E.
collection PubMed
description [Image: see text] Oncogenic mutations of Ras at codons 12, 13, or 61, that render the protein constitutively active, are found in ∼16% of all cancer cases. Among the three major Ras isoforms, KRAS is the most frequently mutated isoform in cancer. Each Ras isoform and tumor type displays a distinct pattern of codon-specific mutations. In colon cancer, KRAS is typically mutated at codon 12, but a significant fraction of patients have mutations at codon 13. Clinical data suggest different outcomes and responsiveness to treatment between these two groups. To investigate the differential effects upon cell status associated with KRAS mutations we performed a quantitative analysis of the proteome and phosphoproteome of isogenic SW48 colon cancer cell lines in which one allele of the endogenous gene has been edited to harbor specific KRAS mutations (G12V, G12D, or G13D). Each mutation generates a distinct signature, with the most variability seen between G13D and the codon 12 KRAS mutants. One notable example of specific up-regulation in KRAS codon 12 mutant SW48 cells is provided by the short form of the colon cancer stem cell marker doublecortin-like Kinase 1 (DCLK1) that can be reversed by suppression of KRAS.
format Online
Article
Text
id pubmed-4356034
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-43560342015-03-24 Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations Hammond, Dean E. Mageean, Craig J. Rusilowicz, Emma V. Wickenden, Julie. A. Clague, Michael J. Prior, Ian A. J Proteome Res [Image: see text] Oncogenic mutations of Ras at codons 12, 13, or 61, that render the protein constitutively active, are found in ∼16% of all cancer cases. Among the three major Ras isoforms, KRAS is the most frequently mutated isoform in cancer. Each Ras isoform and tumor type displays a distinct pattern of codon-specific mutations. In colon cancer, KRAS is typically mutated at codon 12, but a significant fraction of patients have mutations at codon 13. Clinical data suggest different outcomes and responsiveness to treatment between these two groups. To investigate the differential effects upon cell status associated with KRAS mutations we performed a quantitative analysis of the proteome and phosphoproteome of isogenic SW48 colon cancer cell lines in which one allele of the endogenous gene has been edited to harbor specific KRAS mutations (G12V, G12D, or G13D). Each mutation generates a distinct signature, with the most variability seen between G13D and the codon 12 KRAS mutants. One notable example of specific up-regulation in KRAS codon 12 mutant SW48 cells is provided by the short form of the colon cancer stem cell marker doublecortin-like Kinase 1 (DCLK1) that can be reversed by suppression of KRAS. American Chemical Society 2015-01-19 2015-03-06 /pmc/articles/PMC4356034/ /pubmed/25599653 http://dx.doi.org/10.1021/pr501191a Text en Copyright © 2015 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle Hammond, Dean E.
Mageean, Craig J.
Rusilowicz, Emma V.
Wickenden, Julie. A.
Clague, Michael J.
Prior, Ian A.
Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
title Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
title_full Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
title_fullStr Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
title_full_unstemmed Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
title_short Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
title_sort differential reprogramming of isogenic colorectal cancer cells by distinct activating kras mutations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356034/
https://www.ncbi.nlm.nih.gov/pubmed/25599653
http://dx.doi.org/10.1021/pr501191a
work_keys_str_mv AT hammonddeane differentialreprogrammingofisogeniccolorectalcancercellsbydistinctactivatingkrasmutations
AT mageeancraigj differentialreprogrammingofisogeniccolorectalcancercellsbydistinctactivatingkrasmutations
AT rusilowiczemmav differentialreprogrammingofisogeniccolorectalcancercellsbydistinctactivatingkrasmutations
AT wickendenjuliea differentialreprogrammingofisogeniccolorectalcancercellsbydistinctactivatingkrasmutations
AT claguemichaelj differentialreprogrammingofisogeniccolorectalcancercellsbydistinctactivatingkrasmutations
AT prioriana differentialreprogrammingofisogeniccolorectalcancercellsbydistinctactivatingkrasmutations